Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20020995 | 0.74 | KDM4E (0.32) | POLB | |
| SCHEMBL17570522 | 0.74 | — | — | |
| SCHEMBL17320486 | 0.74 | — | — | |
| SCHEMBL15165092 | 0.74 | POLB (0.33) | POLBMAPT | |
| SCHEMBL17570515 | 0.69 | — | — | |
| SCHEMBL12538485 | 0.69 | P2RX7 (0.50) | — | |
| SCHEMBL898668 | 0.67 | — | — | |
| SCHEMBL24534611 | 0.65 | — | — | |
| SCHEMBL4545334 | 0.65 | POLB (0.31) | POLBMAPT | |
| SCHEMBL14498497 | 0.64 | PTPN1 (0.30) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| EP-1133481-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| EP-1001946-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000031049-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-R AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1001946-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | POLB 3089/4885MAPT 3444/4885 |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | ITK, HRH4, BLK | POLB 1822/4885MAPT 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.